Vimta Labs Limited has informed the Exchange about Investor Presentation
VIMTALABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vimta Labs shared its Q1 FY26 investor presentation with the exchanges. Total Income came in at Rs 993 Mn, up 3.4% YoY and 31.4% QoQ. EBITDA stood at Rs 354 Mn with a margin of 35.7%, while PAT was Rs 189 Mn at a 19.0% margin and EPS of Rs 4.2. CAPEX outflow during the quarter was Rs 241.2 Mn. For the full year FY25, Total Income grew 19.1% YoY to Rs 3,482 Mn with EBITDA margin expanding to 36.2%. The company highlighted its leadership position: #1 in India in Pharma Analytical and Food Testing, with 36% of pharma analytical revenue and 75% of clinical research revenue coming from overseas. Market cap stands at Rs 2,001 Cr with a nearly debt-free balance sheet (Debt Rs 70 Mn, Cash Rs 150 Mn, D/E 0.02).
The presentation reinforces Vimta's strong financial profile — consistent margin expansion, a 25% revenue CAGR over FY20-FY25, and a net cash position. No new material catalysts were disclosed; the filing is largely a recap of recent quarterly performance and existing growth strategies around capacity expansion, new market penetration, and operational excellence.